Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain
Status: | Recruiting |
---|---|
Conditions: | Pain |
Therapuetic Areas: | Musculoskeletal |
Healthy: | No |
Age Range: | 7 - 12 |
Updated: | 6/9/2018 |
Start Date: | October 15, 2017 |
End Date: | September 2019 |
Contact: | Robert J Shulman, MD |
Email: | rshulman@bcm.edu |
Phone: | 713-798-7178 |
Aim 1 - Determine the PKD of PMO (menthol) in children with functional abdominal pain (FAP)
(n=30). Aim 2 - Determine effect of PMO administration on gut microbiome composition and
contractile activity/gut transit rate.
(n=30). Aim 2 - Determine effect of PMO administration on gut microbiome composition and
contractile activity/gut transit rate.
Children with functional abdominal pain (FAP) ages 7-12 years (n=30) will be recruited.
The study participants will be admitted to the Children's Nutrition Research Center. A
medical history and a general physical examination performed by the investigator or the
research nurse. The height, weight, and vital signs (pulse rate, respiratory rate, and seated
blood pressure) will be obtained. After application of a topical anesthetic to the site
chosen for study-related blood sampling, a cannula will be inserted e to obtain repeated
blood samples.
At approximately 0900, subjects will receive one of three doses of PMO as a single oral dose.
Immediately prior to administration of the PMO, a blood sample will be obtained to measure
total menthol concentration and leukocytes for isolation of DNA for CYP2A6 and UGT2B7
genotyping.
After PMO administration, repeated blood samples will be obtained over 24 hours.
At 2 hours after PMO administration, participants will be given a standardized meal and will
eat ad libitum thereafter.
After completion of the final (24 hours) blood samples, vital signs will be reassessed and
the venous cannula removed. Parents will receive a follow-up call from the research
coordinator to access/evaluate if any adverse effects from dose or blood sampling received at
the overnight study visit.
Prior to and after administration of peppermint oil (PMO) for 1 week at the dose defined
above, children will undergo measurement of gut microbiome composition and GI motility and
transit time. At the time of the stool collection, the child will also keep a 3 day diet
history.
The study participants will be admitted to the Children's Nutrition Research Center. A
medical history and a general physical examination performed by the investigator or the
research nurse. The height, weight, and vital signs (pulse rate, respiratory rate, and seated
blood pressure) will be obtained. After application of a topical anesthetic to the site
chosen for study-related blood sampling, a cannula will be inserted e to obtain repeated
blood samples.
At approximately 0900, subjects will receive one of three doses of PMO as a single oral dose.
Immediately prior to administration of the PMO, a blood sample will be obtained to measure
total menthol concentration and leukocytes for isolation of DNA for CYP2A6 and UGT2B7
genotyping.
After PMO administration, repeated blood samples will be obtained over 24 hours.
At 2 hours after PMO administration, participants will be given a standardized meal and will
eat ad libitum thereafter.
After completion of the final (24 hours) blood samples, vital signs will be reassessed and
the venous cannula removed. Parents will receive a follow-up call from the research
coordinator to access/evaluate if any adverse effects from dose or blood sampling received at
the overnight study visit.
Prior to and after administration of peppermint oil (PMO) for 1 week at the dose defined
above, children will undergo measurement of gut microbiome composition and GI motility and
transit time. At the time of the stool collection, the child will also keep a 3 day diet
history.
Inclusion Criteria:
1. Children ages 7-12 years old
2. They will be able to complete the protocol
3. A child will be recruited if the medical evaluation reveals no organic reason for the
abdominal pain
Exclusion Criteria:
1. Children who have had past bowel surgery;
2. A child with documented GI disorders (e.g., Crohn's disease);
3. A child with a serious chronic medical condition (e.g., diabetes);
4. A child with a weight and/or height < 2 SD for age;
5. Children with chronic conditions with GI symptoms (e.g., cystic fibrosis);
6. Children with autism spectrum disorder, significant developmental delay, psychosis,
depression, or a history of bipolar disorder;
7. Children who have been treated with antibiotics/probiotics within 2 mo. (because of
effects on microbiome analysis).
8. Children who speak only Spanish
We found this trial at
1
site
6621 Fannin St
Houston, Texas 77030
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Robert J. Shulman
Phone: 713-798-7005
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
Click here to add this to my saved trials